Male/female adults
Conditions
Interventions
None listed
Sponsors
CPCC Company Limited
DiveDot Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female aged between 40 and 70 at the time of consent. 2. Individuals who meet any of the following conditions: 2-1. Have siblings who have had colorectal cancer and are conscious of their high cancer risk. 2-2. Have parents who have had colorectal cancer and are conscious of their high cancer risk. 2-3. Have siblings who have had stomach cancer, esophageal cancer, or breast cancer and are conscious of their high cancer risk. 2-4. Have parents who have had stomach cancer, esophageal cancer, or breast cancer and are conscious of their high cancer risk. 3. Individuals who are able to give informed consent to participate in this study after receiving a detailed explanation of the protocol and understanding its contents.
Exclusion criteria
Exclusion criteria: 1. Individuals who have been diagnosed with cancer or are currently suffering from cancer. 2. Individuals who are participating in, have participated in within the four weeks prior to the current trial, or are planning to participate in clinical trials of pharmaceuticals or health foods. 3. Individuals with previous and/or current medical history of serious diseases in the heart, liver, kidney, digestive organs. 4. Individuals diagnosed with a mental illness such as depression or undergoing treatment within six months from the time of consent. 5. Females who are pregnant or lactating, and those who intend to become pregnant during the trial period. 6. Individuals who donated 200 mL of their blood or blood components within the last month. 7. Individuals who donated 400 mL of his blood within the last 3 months. 8. Individuals who donated 400 mL of her blood within the last 4 months. 9. Individuals who have had a total of 1200 mL of his blood collected within the last 12 months, including in this study. 10. Individuals who have had a total of 800 mL of her blood collected within the last 12 months, including in this study. 11. Individuals deemed unsuitable for participation in the trial by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood microRNA analysis Participant interviews | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Clinical Planning Department
Outcome results
None listed